Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab

Nivolumab has shown good prognosis in renal cell carcinoma (RCC) patients previously treated with targeted therapy. We aimed to study irAE (immune-related adverse event) due to nivolumab and numbers of previous treatment lines in RCC patients. Between October 2016 and November 2019, 114 patients wer...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Medicine (Baltimore)
Huvudupphovsmän: Mizutani, Kosuke, Ito, Toshiki, Takahara, Kiyoshi, Ando, Ryosuke, Ishihara, Takuma, Yasui, Takahiro, Shiroki, Ryoichi, Miyake, Hideaki, Koie, Takuya
Materialtyp: Artigo
Språk:Inglês
Publicerad: Lippincott Williams & Wilkins 2021
Ämnen:
7300
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC8021322/
https://ncbi.nlm.nih.gov/pubmed/33787647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000025402
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk